1.06
price up icon1.92%   0.02
 
loading

Imunon Inc Aktie (IMNN) Neueste Nachrichten

pulisher
Sep 29, 2026

IMUNON Converts $1.2 Million of Debt-to-Equity - GlobeNewswire

Sep 29, 2026
pulisher
Sep 29, 2026

A debt swap cuts IMUNON’s outstanding debt by about 43%, with no common shares issued. - Stock Titan

Sep 29, 2026
pulisher
Sep 28, 2026

A 7,169-share salary award leaves Imunon (IMNN) chair with 103,921 shares held directly. - Stock Titan

Sep 28, 2026
pulisher
Sep 28, 2026

Part of the CEO’s salary came as stock: Imunon (IMNN) granted Stacy Lindborg 6,697 shares. - Stock Titan

Sep 28, 2026
pulisher
Sep 28, 2026

At $1.41 a share, Imunon (IMNN) granted its medical chief 4,390 shares in place of part of his cash salary. - Stock Titan

Sep 28, 2026
pulisher
Sep 16, 2026

Imunon Inc (NASDAQ: IMNN) Share Price, IMNN Stock News, IMNN Share Price & Updates - kalkine.com.au

Sep 16, 2026
pulisher
Sep 15, 2026

Imunon (IMNN) chair takes stock instead of cash pay - Stock Titan

Sep 15, 2026
pulisher
Sep 15, 2026

Imunon (IMNN) CEO adds 5,504 shares in stock grant - Stock Titan

Sep 15, 2026
pulisher
Sep 15, 2026

Imunon (IMNN) pays its chief medical officer in stock - Stock Titan

Sep 15, 2026
pulisher
Sep 11, 2026

IMUNON partners with National Cancer Institute to expand IL-12 DNA plasmid beyond ovarian cancer - AllSci

Sep 11, 2026
pulisher
Sep 10, 2026

Imunon (IMNN) Partners with NCI on IMNN-001 Immunotherapy Amid V - GuruFocus

Sep 10, 2026
pulisher
Sep 10, 2026

IMUNON Enters CRADA with NCI’s CTEP to Advance IMNN-001 in New Cancer Indications and Combinations - Quiver Quantitative

Sep 10, 2026
pulisher
Sep 10, 2026

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001 - Yahoo Finance

Sep 10, 2026
pulisher
Sep 10, 2026

Imunon schedules R&D day for Sept. 23 to discuss IL-12 therapy By Investing.com - Investing.com Australia

Sep 10, 2026
pulisher
Sep 10, 2026

Imunon schedules R&D day for Sept. 23 to discuss IL-12 therapy - Investing.com Australia

Sep 10, 2026
pulisher
Sep 09, 2026

Imunon schedules R&D day for Sept. 23 to discuss IL-12 therapy - Investing.com Canada

Sep 09, 2026
pulisher
Sep 09, 2026

Imunon schedules R&D day for Sept. 23 to discuss IL-12 therapy - Investing.com UK

Sep 09, 2026
pulisher
Sep 09, 2026

IMUNON Announces Full Agenda and Speaker Lineup Ahead of - GlobeNewswire

Sep 09, 2026
pulisher
Sep 09, 2026

Imunon schedules R&D day for Sept. 23 to discuss IL-12 therapy - Investing.com Nigeria

Sep 09, 2026
pulisher
Sep 08, 2026

Imunon (IMNN) Slips 2.5% to $1.54, Approaching Critical Support at $1.46Stock Analysis - siam.in

Sep 08, 2026
pulisher
Sep 02, 2026

Imunon (IMNN) Slips 2.5% to $1.56 as Range-Bound Trading Keeps Key Levels in FocusCharm Flow - siam.in

Sep 02, 2026
pulisher
Sep 01, 2026

Imunon Inc (IMNN) Insider Sell: General Counsel and Corp Sec Susan Eylward Sells 2,525 Shares - GuruFocus

Sep 01, 2026
pulisher
Sep 01, 2026

Insider at Imunon (NASDAQ: IMNN) logs new stock trade - Stock Titan

Sep 01, 2026
pulisher
Sep 01, 2026

Imunon (IMNN) insider reports new stock trade - Stock Titan

Sep 01, 2026
pulisher
Sep 01, 2026

Imunon (IMNN) counsel takes salary in stock, then sells the same number of shares days later - Stock Titan

Sep 01, 2026
pulisher
Aug 26, 2026

Imunon to host R&D day on phase 3 ovarian cancer trial - Investing.com Canada

Aug 26, 2026
pulisher
Aug 26, 2026

Imunon to host R&D day on phase 3 ovarian cancer trial - Investing.com India

Aug 26, 2026
pulisher
Aug 26, 2026

Imunon to host R&D day on Sept. 23 for ovarian cancer therapy - Investing.com India

Aug 26, 2026
pulisher
Aug 26, 2026

Imunon to host R&D day on phase 3 ovarian cancer trial - Investing.com UK

Aug 26, 2026
pulisher
Aug 26, 2026

Imunon to host R&D day on Sept. 23 for ovarian cancer therapy - Investing.com UK

Aug 26, 2026
pulisher
Aug 26, 2026

Imunon to host R&D day on phase 3 ovarian cancer trial - Investing.com

Aug 26, 2026
pulisher
Aug 25, 2026

Imunon (IMNN) Financial Update: EPS Prints Above Forecast on the Day; The Stock Ends Down 3.05% in the Current UpdateGross Profit Margin - dars.gov.et

Aug 25, 2026
pulisher
Aug 23, 2026

Imunon (IMNN) Q2 2026 Results: The Available Earnings Metric Delivers a Beat on the Day; After Earnings: The Stock Records a 3.80% Increase in the Current UpdateQuarterly Profit Report - vinanet.vn

Aug 23, 2026
pulisher
Aug 23, 2026

Imunon (IMNN) Q2 2026 Results: The Available Earnings Metric Delivers a Beat on the Day; After Earnings: The Stock Records a 3.80% Increase in the Current UpdateGuidance vs Actual - dars.gov.et

Aug 23, 2026
pulisher
Aug 22, 2026

Imunon Earnings Call Highlights Survival Gains, Cash Needs - TipRanks

Aug 22, 2026
pulisher
Aug 18, 2026

Imunon (IMNN) Q2 2026 Filing Snapshot: The Bottom-Line Figure Outpaces Its Comparison in the Latest Session; Stock Move: Shares Move 1.25% Lower on the DayEarnings Revision Upgrade - vinanet.vn

Aug 18, 2026
pulisher
Aug 17, 2026

Imunon (IMNN) General Counsel and Corp Sec Susan Eylward Sells 2,449 Shares - GuruFocus

Aug 17, 2026
pulisher
Aug 17, 2026

Imunon (IMNN) CEO takes 6,615 shares instead of cash pay - Stock Titan

Aug 17, 2026
pulisher
Aug 17, 2026

Imunon (IMNN) pays CMO with 3,516-share stock grant - Stock Titan

Aug 17, 2026
pulisher
Aug 17, 2026

Imunon (IMNN) pays executive chair with 7,147 shares - Stock Titan

Aug 17, 2026
pulisher
Aug 17, 2026

Imunon (IMNN) counsel gets stock in lieu of pay, then sells 2,449 shares - Stock Titan

Aug 17, 2026
pulisher
Aug 16, 2026

Imunon (IMNN) Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 4.43% BounceProduct Revenue Analysis - vinanet.vn

Aug 16, 2026
pulisher
Aug 15, 2026

Imunon Inc. (IMNN) Advances 4.43% as Biotech Stock Tests Key Resistance at $1.73Fair Value Gap - dars.gov.et

Aug 15, 2026
pulisher
Aug 15, 2026

Imunon Inc. (IMNN) Advances 4.43% as Biotech Stock Tests Key Resistance at $1.73Gamma Exposure - vinanet.vn

Aug 15, 2026
pulisher
Aug 15, 2026

Imunon Inc. (IMNN) Advances 4.43% as Biotech Stock Tests Key Resistance at $1.73Sector Neutral Pair - careplusvn.com

Aug 15, 2026
pulisher
Aug 15, 2026

Imunon Inc. (IMNN) Advances 4.43% as Biotech Stock Tests Key Resistance at $1.73Triple MA Cross - dars.gov.et

Aug 15, 2026
pulisher
Aug 14, 2026

Armistice Capital (IMNN) discloses 9.99% Imunon stake via Master Fund - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025 - kalkine.ca

Aug 14, 2026
pulisher
Aug 12, 2026

Earnings call transcript: Imunon beats Q2 2026 EPS forecast as shares stay weak - Investing.com UK

Aug 12, 2026
pulisher
Aug 12, 2026

Maxim Group Maintains Imunon(IMNN.US) With Buy Rating, Maintains Target Price $10 - Moomoo

Aug 12, 2026
$7.50
price up icon 1.35%
$10.27
price up icon 0.39%
$5.74
price up icon 5.03%
$18.93
price up icon 5.17%
$10.91
price up icon 6.03%
WVE WVE
$3.19
price up icon 3.24%
Kapitalisierung:     |  Volumen (24h):